284 related articles for article (PubMed ID: 16495239)
1. In vitro activity of novel rifamycins against rifamycin-resistant Staphylococcus aureus.
Murphy CK; Mullin S; Osburne MS; van Duzer J; Siedlecki J; Yu X; Kerstein K; Cynamon M; Rothstein DM
Antimicrob Agents Chemother; 2006 Mar; 50(3):827-34. PubMed ID: 16495239
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of novel rifamycin derivatives against rifamycin-sensitive and -resistant Staphylococcus aureus isolates in murine models of infection.
Rothstein DM; Farquhar RS; Sirokman K; Sondergaard KL; Hazlett C; Doye AA; Gwathmey JK; Mullin S; van Duzer J; Murphy CK
Antimicrob Agents Chemother; 2006 Nov; 50(11):3658-64. PubMed ID: 16940074
[TBL] [Abstract][Full Text] [Related]
3. Rifalazil retains activity against rifampin-resistant mutants of Chlamydia pneumoniae.
Rothstein DM; Suchland RJ; Xia M; Murphy CK; Stamm WE
J Antibiot (Tokyo); 2008 Aug; 61(8):489-95. PubMed ID: 18997387
[TBL] [Abstract][Full Text] [Related]
4. Preparation and in vitro anti-staphylococcal activity of novel 11-deoxy-11-hydroxyiminorifamycins.
Li J; Ma Z; Chapo K; Yan D; Lynch AS; Ding CZ
Bioorg Med Chem Lett; 2007 Oct; 17(20):5510-3. PubMed ID: 17826091
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection.
Trampuz A; Murphy CK; Rothstein DM; Widmer AF; Landmann R; Zimmerli W
Antimicrob Agents Chemother; 2007 Jul; 51(7):2540-5. PubMed ID: 17502404
[TBL] [Abstract][Full Text] [Related]
6. Emergence of resistance to rifampin and rifalazil in Chlamydophila pneumoniae and Chlamydia trachomatis.
Kutlin A; Kohlhoff S; Roblin P; Hammerschlag MR; Riska P
Antimicrob Agents Chemother; 2005 Mar; 49(3):903-7. PubMed ID: 15728882
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo antibacterial activities of KRM-1648 and KRM-1657, new rifamycin derivatives.
Fujii K; Tsuji A; Miyazaki S; Yamaguchi K; Goto S
Antimicrob Agents Chemother; 1994 May; 38(5):1118-22. PubMed ID: 8067748
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and antibacterial evaluation of a novel series of rifabutin-like spirorifamycins.
Kim IH; Combrink KD; Ma Z; Chapo K; Yan D; Renick P; Morris TW; Pulse M; Simecka JW; Ding CZ
Bioorg Med Chem Lett; 2007 Mar; 17(5):1181-4. PubMed ID: 17189695
[TBL] [Abstract][Full Text] [Related]
9. Rifamycin resistance, rpoB gene mutation and clinical outcomes of Staphylococcus species isolates from prosthetic joint infections in Republic of Korea.
Lee Y; Kim SS; Choi SM; Bae CJ; Oh TH; Kim SE; Kim UJ; Kang SJ; Jung SI; Park KH
J Glob Antimicrob Resist; 2022 Mar; 28():43-48. PubMed ID: 34920175
[TBL] [Abstract][Full Text] [Related]
10. Activities of the combination of quinupristin-dalfopristin with rifampin in vitro and in experimental endocarditis due to Staphylococcus aureus strains with various phenotypes of resistance to macrolide-lincosamide-streptogramin antibiotics.
Zarrouk V; Bozdogan B; Leclercq R; Garry L; Feger C; Carbon C; Fantin B
Antimicrob Agents Chemother; 2001 Apr; 45(4):1244-8. PubMed ID: 11257041
[TBL] [Abstract][Full Text] [Related]
11. Rifamycin Derivatives Are Effective Against Staphylococcal Biofilms In Vitro and Elutable From PMMA.
Sanchez CJ; Shiels SM; Tennent DJ; Hardy SK; Murray CK; Wenke JC
Clin Orthop Relat Res; 2015 Sep; 473(9):2874-84. PubMed ID: 25896136
[TBL] [Abstract][Full Text] [Related]
12. In vitro time-kill activities of rifalazil, alone and in combination with vancomycin, against logarithmic and stationary cultures of Staphylococcus aureus.
Osburne MS; Rothstein DM; Farquhar R; Murphy CK
J Antibiot (Tokyo); 2006 Feb; 59(2):80-5. PubMed ID: 16629407
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of a new rifamycin derivative against Mycobacterium leprae.
Dhople AM; Dimova V
Arzneimittelforschung; 1996 Feb; 46(2):210-2. PubMed ID: 8720317
[TBL] [Abstract][Full Text] [Related]
14. In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus.
Robertson GT; Bonventre EJ; Doyle TB; Du Q; Duncan L; Morris TW; Roche ED; Yan D; Lynch AS
Antimicrob Agents Chemother; 2008 Jul; 52(7):2313-23. PubMed ID: 18443108
[TBL] [Abstract][Full Text] [Related]
15. Rifamycin inhibition of WT and Rif-resistant Mycobacterium tuberculosis and Escherichia coli RNA polymerases in vitro.
Gill SK; Garcia GA
Tuberculosis (Edinb); 2011 Sep; 91(5):361-9. PubMed ID: 21704562
[TBL] [Abstract][Full Text] [Related]
16. Differential effect of rpoB mutations on antibacterial activities of rifampicin and KRM-1648 against Staphylococcus aureus.
Wichelhaus T; Schäfer V; Brade V; Böddinghaus B
J Antimicrob Chemother; 2001 Feb; 47(2):153-6. PubMed ID: 11157898
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of coumermycin alone or in combination against Staphylococcus aureus and Staphylococcus epidermidis.
Van der Auwera P; Klastersky J
Drugs Exp Clin Res; 1986; 12(4):307-11. PubMed ID: 3013562
[TBL] [Abstract][Full Text] [Related]
18. Enhanced activity of rifalazil in combination with levofloxacin, linezolid, or mupirocin against Staphylococcus aureus in vitro.
Osburne MS; Murphy CK; Rothstein DM
J Antibiot (Tokyo); 2006 May; 59(5):303-8. PubMed ID: 16883781
[TBL] [Abstract][Full Text] [Related]
19. Antibiotic activity against intraleukocytic Staphylococcus aureus in vitro and in experimental mastitis in mice.
Craven N; Anderson JC
Am J Vet Res; 1983 Apr; 44(4):709-12. PubMed ID: 6553464
[TBL] [Abstract][Full Text] [Related]
20. Rifampin-resistant RNA polymerase mutants of Chlamydia trachomatis remain susceptible to the ansamycin rifalazil.
Suchland RJ; Bourillon A; Denamur E; Stamm WE; Rothstein DM
Antimicrob Agents Chemother; 2005 Mar; 49(3):1120-6. PubMed ID: 15728912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
